drugset / Trial / NCT01222286
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-07
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPH2101 | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | IPH2101 | Monoclonal antibody | 2 mg/kg | Intravenous |